
This study evaluates (i) constitutive levels of oncogene and p53 transcripts in chronic phase CML patients and (ii) their modulations subsequent to in vivo therapy with rIFN-alpha 2c.
[study; ;This] 

[evaluates; ;study] 

[i; ;constitutive levels of oncogene and p53 transcripts in chronic phase CML patients] 

[ii; ;their modulations subsequent to in vivo therapy with rIFN-alpha 2c] 

[and@2; ;constitutive levels of oncogene and p53 transcripts in chronic phase CML patients] 

[and@2; ;their modulations subsequent to in vivo therapy with rIFN-alpha 2c] 

[evaluates; ;levels] 

[levels; ;constitutive] 

[levels;of;oncogene] 

[levels;of;p53 transcripts] 

[and@1; ;oncogene] 

[and@1; ;p53 transcripts] 

[levels;in@1;chronic phase CML patients] 

[CML patients; ;chronic phase] 

[phase; ;chronic] 

[patients; ;CML] 

[evaluates; ;modulations] 

[modulations; ;their] 

[subsequent; ;modulations] 

[subsequent;to;therapy] 

[therapy;in@2;vivo] 

[therapy;with;rIFN-alpha 2c] 

